Spark Therapeutics Soars After Raising $161M In Upsized IPO
Venture capital-backed Spark Therapeutics Inc., a gene therapy-focused biotech company developing drugs to treat blindness, raised $161 million in an upsized initial public offering and promptly watched shares more than double...To view the full article, register now.
Already a subscriber? Click here to view full article